Dear Sir,

In a recent study by Kullmann and colleagues [1], the authors showed that brain insulin sensitivity predicts weight loss at follow-up of nearly 10 years. Furthermore, in a cross-sectional experiment, good hypothalamic insulin responsiveness was associated with lesser visceral fat mass, while no correlation was detected with subcutaneous fat mass. However, origins and mechanisms of brain insulin resistance remain elusive [2].

Whereas definition of systemic insulin resistance is based on tissue-level studies where several molecular defects have been established [3, 4], characterization of human brain metabolism relies on different in vivo neuroimaging methods such as positron emission tomography (PET), hemodynamic imaging (functional magnetic resonance imaging, fMRI), and neuromagnetic measures (magnetoencephalography, MEG). Accordingly, definition of brain insulin resistance varies depending on the implemented method: i.e., a blunted cerebrocortical insulin effect when MEG is applied [5], decreased intranasal insulin-induced suppression of hypothalamic blood flow in fMRI [1], and an insulin-induced increase in brain glucose uptake (BGU) in [18F]-fluorodeoxyglucose PET ([18F]-FDG-PET) studies [6]. Unfortunately, multiple measures are rarely used within a single study, and in the absence of a ground truth measurement of brain insulin resistance, the integration of these results is complicated.

It would thus be important to assess the consistency of these measures (MEG, fMRI, and [18F]-FDG-PET), when applied to the same pool of subjects. Second, complementary information within the same subjects would be acquired, since each of these methods characterize different aspects of brain function: MEG measures net effect of the ionic currents in neurons during synaptic transmission, BOLD fMRI measures combination of cerebral blood flow, and cerebral metabolic rate of oxygen, while [18F]-FDG-PET quantifies brain glucose uptake at the whole-brain level and also in specific parts of the organ [7]. Furthermore, these three techniques target at least to some extent different cell types. MEG picks up the neuronal ionic currents, whereas the [18F]-FDG signal in brain PET studies is likely driven by astrocytes [8], and fMRI presumably measures a combination of both.

We have previously reported in two different datasets with subjects undergoing bariatric surgery that increased brain substrate uptake (glucose or free fatty acids) before surgery predicts a worse glycemic control at follow-up [6, 9]. This finding is in line with the longitudinal findings of Kullmann and colleagues: brain insulin resistance and/or higher brain substrate uptake at baseline predicts an unfavorable metabolic outcome at follow-up.

Further, here we demonstrate, using [18F]-FDG-PET, that insulin-induced change in brain glucose uptake (BGU) correlates with visceral but not with subcutaneous fat mass. Data from 44 subjects (11 male/33 female, age 45 years [SD 10], BMI 35 kg/m² [interquartile range 8]), who were studied with [18F]-FDG-PET during fasting and euglycemic hyperinsulinemic clamp with insulin infusion at 40 mU m⁻² min⁻¹ were analyzed. BGU was quantified using dynamic PET imaging, and abdominal visceral and subcutaneous fat mass were measured with MRI as detailed in the original publications [10, 11]. Prior to inclusion, each participant gave written informed consent. The studies were approved by the Ethics Committee of the Hospital District of Southwest Finland and conducted in accordance with the Declaration of Helsinki.

We found (Fig. 1) that change in BGU from fasting to insulin-stimulated state correlated positively with visceral fat mass (r = 0.40, p = 0.007), whereas there was no association between increased BGU and subcutaneous abdominal fat mass, confirming thus the finding of Kullmann and colleagues.
We however found that the cross-talk between brain and visceral fat occurred in conditions of systemic hyperinsulinemia, and thus the activation of the brain-visceral fat axis could arise either through a direct effect of insulin in the brain, or in the visceral fat, or via bidirectional coupling. As for the differences between subcutaneous and visceral fat, it has been previously shown that the autonomic innervation differs in these two fat depots [12], and a previous study has shown that central insulin action through intranasal insulin administration suppresses systemic but not subcutaneous lipolysis in humans [13], suggesting that the visceral and subcutaneous depots are differently affected by central insulin action, a pattern which may explain also the present findings.

Based on the consistency of our findings and those reported by Kullmann et al. and ours that show brain insulin resistance defined as smaller hypothalamic responsiveness to intranasal insulin or as increased BGU during hyperinsulinemic euglycemic clamp relates with visceral fat mass. Moreover, brain insulin resistance assessed with MEG and PET predicts worse metabolic outcome at follow-up (FU). Taken together, brain insulin resistance seems to be involved in the pathogenesis of systemic insulin resistance (b, c). MEG can address cortical areas (pink color), BOLD fMRI can detect perfusion changes in response to stimuli in very small brain areas, like the hypothalamus (red), while PET measures metabolism at the whole-brain or larger regional levels (orange) (the cartoons inside the brain represent neurons and astrocytes) (b).

**Funding** The study was conducted within the Center of Excellence in Cardiovascular and Metabolic Diseases, supported by the Academy of Finland, the University of Turku, Turku University Hospital, Åbo Akademi University, Finnish Diabetes Foundation, and Sigrid Juselius Foundation.

**Compliance with ethical standards** All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study.

**Conflict of interest** The authors declare that they have no conflict of interest.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a

---

**Fig. 1** Change in brain glucose uptake between euglycemic hyperinsulinemic clamp and fasting conditions correlated positively with visceral fat mass, but not with abdominal subcutaneous fat mass. Pink circles are female participants, and blue circles are males (a). The data of Kullmann et al. and ours show that brain insulin resistance defined as smaller hypothalamic responsiveness to intranasal insulin or as increased BGU during hyperinsulinemic euglycemic clamp relates with visceral fat mass. Moreover, brain insulin resistance assessed with MEG and PET predicts worse metabolic outcome at follow-up (FU). Taken together, brain insulin resistance seems to be involved in the pathogenesis of systemic insulin resistance (b, c). MEG can address cortical areas (pink color), BOLD fMRI can detect perfusion changes in response to stimuli in very small brain areas, like the hypothalamus (red), while PET measures metabolism at the whole-brain or larger regional levels (orange) (the cartoons inside the brain represent neurons and astrocytes) (b).
References

1. Kullmann S, Valenta V, Wagner R, Tschritter O, Machann J, HäringHU, et al. Brain insulin sensitivity is linked to adiposity and body fat distribution. Nat Commun. 2020;15(11):1841.

2. Kullmann S, Kleinridders A, Small DM, Fritsche A, HäringHU, Preissl H, et al. Central nervous pathways of insulin action in the control of metabolism and food intake. Lancet Diabetes Endocrinol. 2020;8:524–34.

3. Shepherd PR, Kahn BB. Cellular defects in glucose transport: lessons 80. From animal models and implications for human insulin resistance. In: Moller DE, editor. Insulin Resistance. London: Wiley; 1993. p. 253–300.

4. Olefsky JM, Molina JM. Insulin resistance in man. In: Rifkin H, Porte Jr D, editors. Diabetes Mellitus, vol. 81. 4th ed. New York: Elsevier; 1990. p. 121–53.

5. Tschritter O, Preissl H, Hennige AM, Stumvoll M, Porubska K, Frost R, et al. The cerebrocortical response to hyperinsulinemia is reduced in overweight humans: a magnetoencephalographic study. Proc Natl Acad Sci U S A. 2006;103:12103–8.

6. Rebelos E, Immonen H, Bucci M, Hannukainen JC, Nummenmaa L, Honka MJ, et al. Brain glucose uptake is associated with endogenous glucose production in obese patients before and after bariatric surgery and predicts metabolic outcome at follow-up. Diabetes Obes Metab. 2019;21:218–26.

7. Tataranni PA, DelParigi A. Functional neuroimaging: a new generation of human brain studies in obesity research. Obes Rev. 2003;4(4):229–38.

8. Zimmer ER, Parent MJ, Souza DG, Leuzy A, Lecrux C, Kim H, et al. [18F]FDG PET signal is driven by astroglial glutamate transport. Nat Neurosci. 2017;20:393–5.

9. Rebelos E, Hirvonen J, Bucci M, Pekkarinen L, Nyman M, Hannukainen JC, et al. Brain free fatty acid uptake is elevated in morbid obesity, and is irreversible 6 months after bariatric surgery: A positron emission tomography study. Diabetes Obes Metab. 2020;22:1074–82.

10. Hirvonen J, Virtanen KA, Nummenmaa L, Hannukainen JC, Honka MJ, Bucci M, et al. Effects of insulin on brain glucose metabolism in impaired glucose tolerance. Diabetes. 2011;60:443–7.

11. Dadson P, Landini L, Helmiö M, Hannukainen JC, Immonen H, Honka MJ, et al. Effect of bariatric surgery on adipose tissue glucose metabolism in different depots in patients with or without type 2 diabetes. Diabetes Care. 2016;39:292–9.

12. Kreier F, Kap YS, Mettenleiter TC, van Heijningen C, van der VlietJ, Kalsbeek A, et al. Tracing from fat tissue, liver, and pancreas: a neuroanatomical framework for the role of the brain in type 2 diabetes. Endocrinology. 2006;147:1140–7.

13. Iwen KA, Scherer T, Heni M, Sayk F, Wellnitz T, Machleidt F, et al. Intranasal insulin suppresses systemic but not subcutaneous lipolysis in healthy humans. J Clin Endocrinol Metab. 2014;99:E246–51.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.